NanoSphere Health Sciences Inc. (NSHS.CN)
CAD 0.09
(70.0%)
CAD 0.09
(70.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -9316.00 USD | 83.07% |
| 2022 | -55.01 Thousand USD | 57.93% |
| 2021 | -130.75 Thousand USD | -315.12% |
| 2020 | 60.78 Thousand USD | -47.6% |
| 2019 | 116 Thousand USD | 154.82% |
| 2018 | -211.62 Thousand USD | 94.28% |
| 2017 | -3.7 Million USD | -269.01% |
| 2016 | -1 Million USD | -520.02% |
| 2015 | -161.78 Thousand USD | -143.13% |
| 2014 | -66.54 Thousand USD | -392.26% |
| 2013 | -13.51 Thousand USD | 99.19% |
| 2012 | -1.66 Million USD | 68.44% |
| 2011 | -5.27 Million USD | -11445.05% |
| 2010 | -45.73 Thousand USD | 90.61% |
| 2009 | -486.93 Thousand USD | -548.26% |
| 2008 | -75.11 Thousand USD | 91.97% |
| 2007 | -935.26 Thousand USD | -227.5% |
| 2006 | -285.57 Thousand USD | 9.55% |
| 2005 | -315.74 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -8126.00 USD | 12.77% |
| 2024 Q2 | 8069.00 USD | 199.3% |
| 2023 Q3 | -11.36 Thousand USD | 56.59% |
| 2023 Q2 | -26.19 Thousand USD | 22.04% |
| 2023 Q1 | -33.59 Thousand USD | 38.93% |
| 2023 Q4 | -9316.00 USD | 18.06% |
| 2023 FY | -9316.00 USD | 83.07% |
| 2022 Q4 | -55.01 Thousand USD | 9.45% |
| 2022 Q3 | -60.75 Thousand USD | 31.32% |
| 2022 Q1 | -124.44 Thousand USD | 4.83% |
| 2022 Q2 | -88.45 Thousand USD | 28.92% |
| 2022 FY | -55.01 Thousand USD | 57.93% |
| 2021 Q1 | 42.38 Thousand USD | -30.27% |
| 2021 FY | -130.75 Thousand USD | -315.12% |
| 2021 Q3 | -148.89 Thousand USD | -527.66% |
| 2021 Q4 | -130.75 Thousand USD | 12.18% |
| 2021 Q2 | 34.81 Thousand USD | -17.86% |
| 2020 Q1 | 132.44 Thousand USD | 14.17% |
| 2020 Q4 | 60.78 Thousand USD | -21.21% |
| 2020 Q3 | 77.14 Thousand USD | -25.68% |
| 2020 Q2 | 103.8 Thousand USD | -21.63% |
| 2020 FY | 60.78 Thousand USD | -47.6% |
| 2019 Q2 | -99.24 Thousand USD | 77.06% |
| 2019 FY | 116 Thousand USD | 154.82% |
| 2019 Q1 | -432.6 Thousand USD | -104.42% |
| 2019 Q4 | 116 Thousand USD | 242.14% |
| 2019 Q3 | 33.9 Thousand USD | 134.16% |
| 2018 Q4 | -211.62 Thousand USD | -81.17% |
| 2018 Q2 | -1.06 Million USD | 53.41% |
| 2018 Q1 | -2.28 Million USD | 38.15% |
| 2018 Q3 | -116.81 Thousand USD | 89.05% |
| 2018 FY | -211.62 Thousand USD | 94.28% |
| 2017 Q1 | -873.19 Thousand USD | 13.0% |
| 2017 Q2 | -761.07 Thousand USD | 12.84% |
| 2017 FY | -3.7 Million USD | -269.01% |
| 2017 Q3 | -813.29 Thousand USD | -6.86% |
| 2017 Q4 | -3.7 Million USD | -355.14% |
| 2016 FY | -1 Million USD | -520.02% |
| 2016 Q3 | -1.06 Million USD | -886.62% |
| 2016 Q4 | -1 Million USD | 5.97% |
| 2016 Q1 | -152.63 Thousand USD | 5.93% |
| 2016 Q2 | -108.19 Thousand USD | 29.12% |
| 2015 FY | -161.78 Thousand USD | -143.13% |
| 2015 Q1 | -58.97 Thousand USD | 11.77% |
| 2015 Q2 | -29.53 Thousand USD | 49.91% |
| 2015 Q4 | -162.25 Thousand USD | 5.62% |
| 2015 Q3 | -171.91 Thousand USD | -482.04% |
| 2014 FY | -66.54 Thousand USD | -392.26% |
| 2014 Q1 | -11.34 Thousand USD | 16.05% |
| 2014 Q4 | -66.84 Thousand USD | 15.31% |
| 2014 Q3 | -78.92 Thousand USD | -685.65% |
| 2014 Q2 | -10.04 Thousand USD | 11.47% |
| 2013 FY | -13.51 Thousand USD | 99.19% |
| 2013 Q4 | -13.51 Thousand USD | 45.69% |
| 2013 Q3 | -24.88 Thousand USD | 83.44% |
| 2013 Q2 | -150.32 Thousand USD | 80.74% |
| 2013 Q1 | -780.64 Thousand USD | 53.15% |
| 2012 Q4 | -1.66 Million USD | 34.33% |
| 2012 Q1 | -4.45 Million USD | 15.64% |
| 2012 FY | -1.66 Million USD | 68.44% |
| 2012 Q2 | -3.62 Million USD | 18.58% |
| 2012 Q3 | -2.53 Million USD | 30.03% |
| 2011 Q4 | -5.27 Million USD | 18.51% |
| 2011 FY | -5.27 Million USD | -11445.05% |
| 2011 Q3 | -6.47 Million USD | 21.15% |
| 2011 Q2 | -8.21 Million USD | -91.79% |
| 2011 Q1 | -4.28 Million USD | -9267.48% |
| 2010 Q2 | -413.04 Thousand USD | 12.95% |
| 2010 FY | -45.73 Thousand USD | 90.61% |
| 2010 Q4 | -45.73 Thousand USD | -305.46% |
| 2010 Q1 | -474.48 Thousand USD | 2.56% |
| 2010 Q3 | -11.27 Thousand USD | 97.27% |
| 2009 Q2 | -1819.20 USD | 99.26% |
| 2009 Q4 | -486.93 Thousand USD | -75.22% |
| 2009 FY | -486.93 Thousand USD | -548.26% |
| 2009 Q1 | -245.88 Thousand USD | -227.34% |
| 2009 Q3 | -277.9 Thousand USD | -15176.06% |
| 2008 Q1 | -371.4 Thousand USD | 60.29% |
| 2008 Q4 | -75.11 Thousand USD | 50.29% |
| 2008 Q2 | -272.67 Thousand USD | 26.58% |
| 2008 Q3 | -151.1 Thousand USD | 44.58% |
| 2008 FY | -75.11 Thousand USD | 91.97% |
| 2007 Q3 | -2.97 Million USD | 30.63% |
| 2007 FY | -935.26 Thousand USD | -227.5% |
| 2007 Q4 | -935.26 Thousand USD | 68.55% |
| 2007 Q2 | -4.28 Million USD | -1541.15% |
| 2007 Q1 | -261.23 Thousand USD | 8.52% |
| 2006 Q4 | -285.57 Thousand USD | 6.56% |
| 2006 Q3 | -305.62 Thousand USD | 1.31% |
| 2006 Q2 | -309.68 Thousand USD | -0.12% |
| 2006 FY | -285.57 Thousand USD | 9.55% |
| 2006 Q1 | -309.3 Thousand USD | 2.04% |
| 2005 Q3 | -346.83 Thousand USD | 0.0% |
| 2005 FY | -315.74 Thousand USD | 0.0% |
| 2005 Q4 | -315.74 Thousand USD | 8.96% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -125.08 Thousand CAD | 92.552% |
| Asep Medical Holdings Inc | -44.72 Thousand CAD | 79.169% |
| BetterLife Pharma Inc. | 207.85 Thousand CAD | 104.482% |
| BioVaxys Technology Corp. | -977.00 CAD | -853.531% |
| ChitogenX Inc. | 3.84 Million CAD | 100.243% |
| Rapid Dose Therapeutics Corp. | 2.29 Million CAD | 100.406% |
| Defence Therapeutics Inc. | 1.68 Million CAD | 100.551% |
| Entheon Biomedical Corp. | -344.63 Thousand CAD | 97.297% |
| Gemina Laboratories Ltd. | 284.33 Thousand CAD | 103.276% |
| Glow Lifetech Corp. | 116.15 Thousand CAD | 108.021% |
| Lexston Life Sciences Corp. | -390.4 Thousand CAD | 97.614% |
| Pharmala Biotech Holdings Inc. | 58.49 Thousand CAD | 115.926% |
| Doseology Sciences Inc. | -1.06 Million CAD | 99.121% |
| MYND Life Sciences Inc. | 2.99 Million CAD | 100.311% |
| Nova Mentis Life Science Corp. | -8088.00 CAD | -15.183% |
| PharmaTher Holdings Ltd. | -2.13 Million CAD | 99.563% |
| PreveCeutical Medical Inc. | 3.83 Million CAD | 100.243% |
| Telescope Innovations Corp. | -719.49 Thousand CAD | 98.705% |